Investors in Amgen Inc. AMGN need to pay close attention to the stock based on moves in the options market lately. That is ...

The U.S. FDA recently highlighted Amgen’s role in its real‑time clinical trials initiative, confirming the initiation of ...

New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...

Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating ...

A quantum tech firm that has collaborated with—and received investment from—Amgen is now planning to go public. | A quantum ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

Quick Read Guggenheim trimmed its Amgen (AMGN) stock price target to $340 from $351 while maintaining Neutral, reflecting a ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

Amgen's two patent applications purporting to cover all antibodies that bind and block the PCSK9 receptor involved in LDL cholesterol metabolism fail to satisfy the Patent Act's enablement clause, ...

Food and Drug ‌Administration's Center for Drug ‌Evaluation and Research on Monday ​proposed withdrawing approval of Amgen's drug for a group of rare autoimmune diseases, ‌citing ⁠a lack of proven ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...

Thousand Oaks pharma giant Amgen Inc. is making a series of C-suite changes, triggered by the retirement announcement of ...